DR-391 Identifying cancer causing regulators using high throughput transcriptomics and whole-genomics data
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-391 Identifying cancer causing regulators using high throughput transcriptomics and whole-genomics data
Here, we propose to identify the link between noncoding regulatory mutations and the aberrantly activated regulatory proteins in cancer cells …
DR-378 Optimizing Treatment of Cancers through Integration of Therapeutic-Response-Centric Clinical-Bio Big Data and Multimodal Artificial Intelligence
Summary = We are working on creating a computer program that can analyze different types of cancer using information from genes, …
DR-312 Comparison of the somatic mutational landscape of metastatic breast cancer studies
Metastases are the leading cause of mortality in breast cancer patients. The tumor acquires specific mutations that drive the tumor’s …
DR-272 Uncovering the role of gut bacteria in colorectal cancer tumorigenesis and metastasis
Colorectal cancer (CRC) is the third most common cancer in men and second most common in women worldwide. The intestinal …
DR-381 CHEMOTRANSPORT: exploring influx mediated susceptibility to chemotherapy
To become effective within a tumor cell, chemotherapy needs to be transported into that cell via influx transporters. The activity …
DR-379 Identification of the CDX1/2-GUCY2C-cGMP axis as a driver of primary resistance to anti-EGFR therapies in metastatic colorectal cancer
The approval of anti-EGFR treatments for metastatic colorectal cancer significantly improved patient survival. However, drug resistance remains a significant challenge. …
DR-356 Validation of a prognostic signature based on metabolic profile from unsupervised approach and differential expression
We built a prognostic model based on metabolic profile of patients with head and neck squamous cell carcinoma. We need …
DR-370 Molecular mechanisms underlying the metastatic progression
Metastasis is responsible for the failure of cancer treatment and patient mortality. Thanks to the unprecedented opportunity to study the …
DR-362 Genetic factors of disease progression and therapy response in cutaneous squamous cell carcinoma
Squamous cell cancer (SCC) of the skin is the second most common type of cancer world-wide. While many patients can …
DR-337 Connecting telomere dysfunction, tumorigenesis and cancer evolution using short-read DNA and RNA sequencing data
The Barthel lab uses advanced sequencing and molecular approaches to study the development and evolution of brain tumors. We have …
DR-240 Genomic signatures of HR deficiency in advanced ovarian cancer
Cancers with defects in DNA repair pathways can be sensitive to certain therapies. One way to identify cases with these …
DR-341 Characterization of immunogenicity of mutations
Some tumor show spectacular effect of immunotherapy, while other tumors show only limited response. Finding biomarkers to predict this response, …
Een complete DNA-test biedt bij patiënten met PTO de extra mogelijkheid om erachter te komen waar de kanker is begonnen. Hierdoor wordt vaak de primaire tumor toch gevonden. Daarnaast geeft de test vaak aanknopingspunten voor een gerichte behandeling.